• Company
• US FDA starts review of GC Biopharma’s Alyglo
• by Kim, Jin-Gu Aug 1, 2023 05:33am

• Company
• Pediatric neurofibroma new drug Koselugo will be reimbursed
• by Eo, Yun-Ho Aug 1, 2023 05:33am

• Company
• Will Hanmi be able to develop its own Saxenda for Koreans?
• by Kim, Jin-Gu Aug 1, 2023 05:33am

• Policy
• Incentives for phase 3 among Koreans raise public opinion
• by Nho, Byung Chul Aug 1, 2023 05:33am

• Policy
• Decided to re-discuss reimbursement criteria for Mylotarg
• by Lee, Tak-Sun Jul 31, 2023 05:29am

• Opinion
• [Reporter's view] When will Enhertu's benefit be available?
• by Jul 31, 2023 05:29am

• Policy
• Bill proposed to allow Kymriah’s use at transplant hospital
• by Kim, Jung-Ju Jul 31, 2023 05:28am

• Company
• Equipped with two new drugs this year alone
• by Jul 31, 2023 05:28am

• Company
• Handok will sell original insulin drug Lantus
• by Lee, Tak-Sun Jul 31, 2023 05:28am

• Company
• Reimb of Bayer’s new heart failure drug Verquvo imminent
• by Eo, Yun-Ho Jul 31, 2023 05:28am